Cargando…

An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk

INTRODUCTION: Outcome predictors in use today are prognostic only for hormone receptor-positive (HRpos) breast cancer. Although microarray-derived multigene predictors of hormone receptor-negative (HRneg) and/or triple negative (Tneg) breast cancer recurrence risk are emerging, to date none have bee...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yau, Christina, Sninsky, John, Kwok, Shirley, Wang, Alice, Degnim, Amy, Ingle, James N, Gillett, Cheryl, Tutt, Andrew, Waldman, Fred, Moore, Dan, Esserman, Laura, Benz, Christopher C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978448/ https://www.ncbi.nlm.nih.gov/pubmed/24172169 http://dx.doi.org/10.1186/bcr3567

Ejemplares similares

A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer
por: Yau, Christina, et al.
Publicado: (2010)

Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature
por: Tutt, Andrew, et al.
Publicado: (2008)

Controversial issues in the neoadjuvant treatment of triple-negative breast cancer
por: Fitzpatrick, Amanda, et al.
Publicado: (2019)

Evaluation of NTRK Gene Fusion by Five Different Platforms in Triple-Negative Breast Carcinoma
por: Wu, Shafei, et al.
Publicado: (2021)

Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control
por: de Rinaldis, Emanuele, et al.
Publicado: (2013)

The Triple-Negative Breast Cancer Database: an omics platform for reference, integration and analysis of triple-negative breast cancer data
por: Raju, Rajesh, et al.
Publicado: (2014)

Are triple-negative tumours and basal-like breast cancer synonymous?
por: Rakha, Emad A, et al.
Publicado: (2007)

Molecular characterisation of cell line models for triple-negative breast cancers
por: Grigoriadis, Anita, et al.
Publicado: (2012)

Carcinogenesis of Triple-Negative Breast Cancer and Sex Steroid Hormones
por: Honma, Naoko, et al.
Publicado: (2021)

The Potential of Hormonal Therapies for Treatment of Triple-Negative Breast Cancer
por: Kirkby, Melanie, et al.
Publicado: (2023)

Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial
por: Sipos, O., et al.
Publicado: (2021)

Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer
por: Brito Baleeiro, Renato, et al.
Publicado: (2023)

Hydrophobic Proteome Analysis of Triple Negative and Hormone-Receptor-Positive-Her2-Negative Breast Cancer by Mass Spectrometer
por: Lu, Ming, et al.
Publicado: (2010)

Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer
por: Vos, Hanne, et al.
Publicado: (2021)

Identification of Five Cytotoxicity-Related Genes Involved in the Progression of Triple-Negative Breast Cancer
por: Zhang, Yan, et al.
Publicado: (2022)

Aurora-A kinase oncogenic signaling mediates TGF-β-induced triple-negative breast cancer plasticity and chemoresistance
por: Jalalirad, Mohammad, et al.
Publicado: (2021)

Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer
por: Qiu, Jingdan, et al.
Publicado: (2016)

Triple-negative breast cancer: recent treatment advances
por: Bergin, Alice R T, et al.
Publicado: (2019)

Mouse mammary stem cells express prognostic markers for triple-negative breast cancer
por: Soady, Kelly J, et al.
Publicado: (2015)

Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer
por: Lee, Joyce V., et al.
Publicado: (2022)

Triple-Negative Breast Cancer
por: Chu, Quyen D., et al.
Publicado: (2012)

Triple-negative breast cancer
por: Chacón, Reinaldo D, et al.
Publicado: (2010)

Gonadotropin-releasing hormone receptor inhibits triple-negative breast cancer proliferation and metastasis
por: Chen, Cai-Ping, et al.
Publicado: (2022)

Survival Study of Triple-Negative and Non–Triple-Negative Breast Cancer in a Brazilian Cohort
por: Gonçalves, Homero, et al.
Publicado: (2018)

Unraveling the Genomic-Epigenomic Interaction Landscape in Triple Negative and Non-Triple Negative Breast Cancer
por: Wu, Jiande, et al.
Publicado: (2020)

Genomic characteristics of triple negative apocrine carcinoma: a comparison to triple negative breast cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2023)

Biomimetic Inorganic Nanovectors as Tumor-Targeting Theranostic Platform against Triple-Negative Breast Cancer
por: Wen, Huang, et al.
Publicado: (2023)

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
por: Horiuchi, Dai, et al.
Publicado: (2012)

Delineation of the Germline and Somatic Mutation Interaction Landscape in Triple-Negative and Non-Triple-Negative Breast Cancer
por: Wu, Jiande, et al.
Publicado: (2020)

Unraveling the Pivotal Network of Ultrasound and Somatic Mutations in Triple-Negative and Non-Triple-Negative Breast Cancer
por: Huang, Yunxia, et al.
Publicado: (2023)

Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers
por: Perez, Roberto, et al.
Publicado: (2012)

Author Correction: Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer
por: Lee, Joyce V., et al.
Publicado: (2022)

Phenotypic analysis of breast cell lines – triple negative cells vs expressing hormonal receptors
por: Laranjo, Mafalda, et al.
Publicado: (2010)

Single Hormone Receptor-Positive Metaplastic Breast Cancer: Similar Outcome as Triple-Negative Subtype
por: Mao, Jinqian, et al.
Publicado: (2021)

Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer
por: Harris, Robert J., et al.
Publicado: (2021)

ERβ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer
por: Reese, Jordan M., et al.
Publicado: (2017)

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer
por: Shah, Ami N, et al.
Publicado: (2020)

Outcome for Patients with Triple-Negative Breast Cancer Is Not Dependent on Race/Ethnicity
por: Chu, Quyen D., et al.
Publicado: (2012)

Molecular classification of triple-negative tumors
por: Prat, A, et al.
Publicado: (2011)

Characteristics of triple-negative breast cancer
por: de Ruijter, Tim C., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_rvn1na24rrmaffk5njedanv57i